STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Consumables segment develops and sells scientific materials, such as nucleic acid purification; and designs and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. STRATEC Biomedical AG also develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical Systems AG and changed its name to STRATEC Biomedical AG in April 2011. STRATEC Biomedical AG was founded in 1979 and is headquartered in Birkenfeld, Germany.
Industry, Sector and Symbol
Stock Exchange ETR
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolETR:SBS
Previous Symbol
CUSIPN/A
Phone+49-7082-79160
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees1,208
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable
Stratec Biomedical (ETR:SBS) Frequently Asked Questions
What is Stratec Biomedical's stock symbol?
Stratec Biomedical trades on the ETR under the ticker symbol "SBS."
What price target have analysts set for SBS?
4 analysts have issued 1 year target prices for Stratec Biomedical's shares. Their predictions range from €55.00 to €81.00. On average, they expect Stratec Biomedical's share price to reach €68.25 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View Analyst Price Targets for Stratec Biomedical.
What is the consensus analysts' recommendation for Stratec Biomedical?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stratec Biomedical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stratec Biomedical.
Has Stratec Biomedical been receiving favorable news coverage?
News coverage about SBS stock has trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stratec Biomedical earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Stratec Biomedical's key competitors?
Some companies that are related to Stratec Biomedical include Activecare (ACAR), Advanced Oncotherapy (AVO), Airware Labs (AIRW), Anteo Diagnostics (ADO), Aurora Spine (ASG), Avacta Group (AVCT), Azure Healthcare (AZV), Biosig Technologies (BSGM), Cannabix Technologies (BLOZF), Cochlear (COH), ConvaTec Group (CTEC), Creo Medical Group (CREO), Draegerwerk AG & Co KGaA (DRW3), Electromed (ELMD) and Ellex Medical Lasers (ELXMF).
Who are Stratec Biomedical's key executives?
Stratec Biomedical's management team includes the folowing people:
- Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 51)
- Dr. Robert Siegle, Director of Fin. & HR and Member of Board of Management (Age 51)
- Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 51)
- Mr. Hermann Leistner, Founder & Advisor (Age 72)
- Sandra Eberle, Head of Investor Relations
What is Stratec Biomedical's stock price today?
One share of SBS stock can currently be purchased for approximately €57.20.
What is Stratec Biomedical's official website?
How can I contact Stratec Biomedical?
Stratec Biomedical's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160.
MarketBeat Community Rating for Stratec Biomedical (ETR SBS)
MarketBeat's community ratings are surveys of what our community members think about Stratec Biomedical and other stocks. Vote "Outperform" if you believe SBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
